MAY 15, 2015
8:00 AM – 5:00 PM
The Hub Cira Centre
2929 Arch Street
Philadelphia, PA, 19104

Penn Medicine’s Abramson Cancer Center PRESENTS
ADVANCED THYROID CANCER MASTER CLASS
CME/CE-Certified Course

REGISTER ONLINE AT
PENNCANCER.ORG/CME/THYROID
ADVANCED THYROID CANCER MASTER CLASS

FRIDAY, MAY 15
2015
8:00 AM – 5:00 PM

THE HUB CIRA CENTRE
2929 Arch Street
Philadelphia, PA, 19104

DIRECTIONS AND PARKING

Please note that most conference material will be available online. Please bring your electronic device to view presentations in real time.

OVERVIEW
This activity is designed to educate the multidisciplinary thyroid cancer team in new treatment paradigms for patients with advanced thyroid cancer. The activity will provide information on: the natural course of the disease; determination of failure of traditional therapies (surgery, and RAI); correct determination of tumor burden and progression warranting treatment with systemic therapy; and management of toxicities of systemic therapy.

OBJECTIVES
Upon completion of this course, participants should be able to:

• Identify the patterns of presentation of patients with progressing advanced Medullary and Differentiated RAI refractory thyroid cancer and how to evaluate the clinical tests used to determine appropriate candidates for systemic therapy.

• Explain the role of surgery, radiation therapy, nuclear medicine and endocrinology in the primary management of patients with advanced MTC and RAI refractory DTC.

• Explain the role of kinase inhibitors in the treatment of patients with progressing advanced Medullary and Differentiated RAI refractory thyroid cancer.

WHO SHOULD ATTEND
This activity has been designed for: physicians, mid-level providers such as physicians’ assistants and nurse practitioners, and other health care providers in the fields of: endocrinology, medical oncology; general, endocrine or oncologic surgery; head and neck surgery, radiology, nuclear medicine, and radiation oncology who are involved in the care of patients with thyroid cancer.
AGENDA

8:00 am  Welcome  
Marcia Brose, MD, PhD  Conference Chair  
Joseph Carver, MD  Chief of Staff, Abramson Cancer Center

PART I: EARLY WARNING SIGNS OF POOR OUTCOME

8:15 am  Overview of the Diagnosis and the Early Management of Thyroid Cancer: Early signs of aggressive disease  
Caroline Kim, MD  Endocrinology

8:45 am  Diagnosing Thyroid Cancer on Thyroid Fine Needle Aspiration: Cytomorphology and beyond  
Zubair Baloch, MD  Pathology

9:15 am  Surgery for Advanced and Recurrent Differentiated Thyroid Cancer  
Ara Chalian, MD  Surgery

9:45 am  Maximal Tolerated Dose I-131 Therapy for Advanced Thyroid Cancer and Determination of Iodine Refractory Disease  
Daniel Pryma, MD  Nuclear Medicine

10:15 am  Break

PART II: MANAGEMENT OF MEDULLARY THYROID CANCER

10:30 am  The Early Management of the Medullary Thyroid Cancer Patient  
Douglas Fraker, MD  Surgery

11:00 am  Management of a Rising Calcitonin and Thyroglobulin  
Kate Newbold, MD  Oncology  The Royal Marsden NHS Foundation Trust

11:30 am  Panel Discussion and Case Presentation  
Patient with Recurrent Disease: Role of re-operation and genetics to determine care  
Panel Moderator: Marcia Brose, MD, PhD  
Panel: Ara Chalian, MD  
Douglas Fraker, MD  
Caroline Kim, MD  
Dan Pryma, MD  
Kate Newbold, MD

12:00 pm  Lunch
# PART III: SYSTEMIC TREATMENT OF PROGRESSIVE METASTATIC AND RECURRENT THYROID CANCER

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Department</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 pm</td>
<td>The New Era of Multi-Kinase Inhibitors: When and whom to treat</td>
<td>Francis Worden, MD</td>
<td>Hematology/Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University Of Michigan Comprehensive Cancer Center</td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI- Refractory DTC</td>
<td>Marcia Brose, MD, PhD</td>
<td>Hematology Oncology</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Kinase Inhibitors for Advanced Medullary Thyroid Cancer: Sequencing and what is next?</td>
<td>Rossella Elisei, MD</td>
<td>Endocrinology</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:15 pm</td>
<td>Maximizing Benefit of Multi-Kinase Inhibitors through the Effective Management of Adverse Events</td>
<td>Carolyn Grande, CRNP</td>
<td>Surgery</td>
</tr>
<tr>
<td>2:45 pm</td>
<td>Diagnosis and Pathological Aspects of High Grade and Poorly Differentiated and Anaplastic Thyroid Cancer</td>
<td>Virginia LiVolsi, MD</td>
<td>Pathology</td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Clinical Trials Available for Differentiated Thyroid Cancer (second and third line and adjuvant) and Medullary Thyroid Cancer: Where do we go from here?</td>
<td>Marcia Brose, MD, PhD</td>
<td>Hematology Oncology</td>
</tr>
<tr>
<td>3:45 pm</td>
<td>Case Presentations and Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel Moderator: Francis Worden, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel: Kate Newbold, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rossella Elisei, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carolyn Grande, CRNP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45 pm</td>
<td>Summary</td>
<td>Marcia Brose MD, PhD</td>
<td></td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Meeting Adjournment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPEAKERS

COURSE CHAIR

Marcia Brose, MD, PhD
Assistant Professor
Hematology Oncology Division

GUEST SPEAKERS

Rossella Elisei, MD
Endocrine Unit
Department of Clinical and Experimental Medicine
University of Pisa
Pisa, Italy

Jim Fagin, MD
Chief, Endocrinology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Kate Newbold, MD
Clinical Oncologist
Head and Neck Unit, Thyroid Unit
The Royal Marsden Foundation Trust
London, England

Francis Worden, MD
Associate Professor
University of Michigan Medical Oncology
Ann Arbor, Michigan

PENN MEDICINE FACULTY

Zubair Baloch, MD
Professor, Pathology & Laboratory Medicine

Joseph Carver, MD
Chief of Staff, Abramson Cancer Center

Ara Chalian, MD
Professor, Otorhinolaryngology - Head & Neck Surgery

Douglas Fraker, MD
Jonathan Rhoads Associate Professor, Surgery

Carolyn Grande, CRNP
Nurse Practitioner
Otorhinolaryngology-Head & Neck Surgery

Caroline Kim, MD
Assistant Professor of Clinical Medicine,
Endocrinology, Diabetes and Metabolism Division

Virginia LiVolsi, MD
Professor, Pathology & Laboratory Medicine

Daniel Pryma, MD
Associate Professor
Radiology Nuclear Medicine Division

ABOUT

ABRAMSON CANCER CENTER

PennMedicine.org/Abramson

Penn’s Abramson Cancer Center is dedicated to the eradication of cancer as a cause of human disease and suffering. The Abramson Cancer Center brings together the cancer care and research efforts of Penn Medicine, including: Perelman Center for Advanced Medicine, Smilow Center for Translational Research, Roberts Proton Therapy Center, Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Pennsylvania Hospital, and Chester County Hospital. The Abramson Cancer Center has been continuously designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973. One of only 41 such Centers in the country the Abramson Cancer Center was rated “EXCEPTIONAL” by the NCI at our last competitive review—the highest possible rating a Center can receive.
The registration fee for physicians is $400.00. For non-Penn residents, fellows, nurses, and other healthcare professionals, the fee is $200.00. For faculty, staff, residents, fellows, and/or students of the University of Pennsylvania, the fee is $200.00. Registration includes breakfast, lunch, breaks, and course syllabus. Parking fees are not covered by this course.

For additional information please contact Barbara Lopez at lopez@upenn.edu.

**REGISTER ONLINE AT PENNCANCER.ORG/CME/THYROID**

**ACCREDITATION AND DESIGNATION OF CREDIT**

**ACCREDITATION**

**PHYSICIANS:** The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**NURSES:** The Hospital of the University of Pennsylvania, Department of Nursing Education, Innovation and Professional Development is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

**DESIGNATION OF CREDIT**

**PHYSICIANS:** The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSES:** This activity has been approved for 7.75 contact hours.

**DISCLOSURES**

The Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, adheres to the ACCME Standards for Commercial Support. Faculty disclosure information will be made available during the activity. Faculty members are also expected to disclose to participants any discussion of off-label and / or investigational use of pharmaceutical products or devices within their presentations.
CANCELLATION POLICY
The University reserves the right to cancel or postpone any course due to unforeseen circumstances. In the event of cancellation or postponement, the University will notify all pre-registrants but is not responsible for any related costs or expenses to participants, including cancellation fees assessed by hotels, airlines and travel agencies.

SERVICES FOR THE DISABLED
If special arrangements are required for an individual with a disability to attend this meeting, please contact Barbara Lopez at 215-614-1954, no later than April 15, 2015.

NONDISCRIMINATION STATEMENT
The University of Pennsylvania values diversity and seeks talented students, faculty and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, color, sex, sexual orientation, gender identity, religion, creed, national or ethnic origin, citizenship status, age, disability, veteran status or any other legally protected class status in the administration of its admissions, financial aid, educational or athletic programs, or other University-administered programs or in its employment practices. Questions or complaints regarding this policy should be directed to the Executive Director of the Office of Affirmative Action and Equal Opportunity Programs, Sansom Place East, 3600 Chestnut Street, Suite 228, Philadelphia, PA 19104-6106; or (215) 898-6993 (Voice).
Penn Medicine’s Abramson Cancer Center PRESENTS
ADVANCED THYROID CANCER MASTER CLASS
CME/CE-Certified Course

MAY 15, 2015 8:00 AM – 5:00 PM

REGISTER ONLINE AT PENNCANCER.ORG/CME/THYROID